comparemela.com

Latest Breaking News On - Susan galbraith - Page 1 : comparemela.com

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Susan galbraithKen takeshitaDaiichi sankyoEuropean society for medical oncology congressMedical oncology

AstraZeneca experimental lung cancer drug shows promising results

AstraZeneca’s experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Ken takeshitaDaiichi sankyoSusan galbraith

AstraZeneca-Daiichi s Dato-DXd didn t prove OS benefit in phase 3

Daiichi Sankyo and ADC partner AstraZeneca have already filed Dato-DXd with the FDA, but the latest readout casts a shadow over the application.

David fredricksonRd ken takeshitaDaiichi sankyoSusan galbraithEuropean society for medical oncologyFierce biotechEuropean societyMedical oncologyGilead science trodelvy

Dato-DXd Elicits Clinically Meaningful OS Improvement in Previously Treated, Advanced NSCLC

Dato-DXd Elicits Clinically Meaningful OS Improvement in Previously Treated, Advanced NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoKen takeshitaSusan galbraith

Why Is AstraZeneca Stock Trading Lower On Tuesday? - AstraZeneca (NASDAQ:AZN)

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

Susan galbraithDaiichi sankyoAstrazeneca plcEuropean society for medical oncologyAstrazeneca targets ambitiousEuropean societyMedical oncologyExecutive vice president

vimarsana © 2020. All Rights Reserved.